Siemens expands its imaging portfolio with the addition of the Biograph TruePoint 16-slice PET•CT* imager. The Biograph TruePoint PET•CT imaging family is the first portfolio of imaging systems to include High-Definition PET•CT and now expands its offering with 16-slice CT capabilities.
”The introduction of this particular system is critical as we continue to search for the balance between innovation and access. The likelihood that universal adoption of PET•CT technology will increase with accessibility is a shared industry vision. As an industry leader, it is our responsibility to make that vision more readily attainable,” said Michael Reitermann, CEO, Molecular Imaging, Siemens Healthcare. “The Biograph TruePoint 16-slice PET•CT is a means to achieve that end, with high performance technology housed in an economical package.”
As the U.S. and international economies struggle to increase the quality of patient care and, simultaneously, reduce healthcare costs, Biograph TruePoint 16-slice PET•CT represents a viable solution for healthcare providers. Offering an affordable and reliable imaging system with high-performance capabilities, the 16-slice Biograph PET•CT offers features, such as High-Definition PET and routine 10-minute, whole-body imaging.
The system is built for patient comfort and reflects features of the Siemens flagship Biograph mCT model. It is equipped with a 500-pound (227 kg) capacity patient bed and efficient workflow system. The system offers faster scan speeds at lower patient doses; important when patients need multiple scans for oncology treatment planning and follow-up.
The complete Biograph family of PET•CT imagers now offers options in TruePoint PET•CT for 6-, 16-, 40- and 64-slice CT configurations, as well as the Biograph mCT technology platform with 40-, 64- and 128-CT slice capabilities. The expanding Biograph family of imagers continues to be a comprehensive portfolio of solutions with upgrade possibilities and non-obsolescence protection. The new Biograph 16-slice PET•CT system is also mobile-ready, equipped to maximize on-location patient throughput with fast, 10-minute imaging.
The Biograph 16-slice PET•CT offers 2 mm uniform PET resolution throughout the field of view and a two-time improvement in signal-to-noise ratio, which provides for small lesion detection. Fast scanning and low patient radiation dose is accomplished through Siemens TrueV extended PET field of view. Providers can achieve scans at twice the scan speed or half the patient dose.
Siemens’ industry-leading dose protection, Care Dose 4D, is also included with Biograph TruePoint systems. With advanced imaging tools, the Biograph 16-slice PET•CT system offers an affordable and reliable imaging solution that can satisfy the needs of an institution of any size, and is able to grow at the same rate as clinical requirements dictate.
The Siemens Healthcare Sector is one of the world’s largest suppliers to the healthcare industry. The company is a renowned medical solutions provider with core competence and innovative strength in diagnostic and therapeutic technologies as well as in knowledge engineering, including information technology and system integration. With its laboratory diagnostics acquisitions, Siemens Healthcare is the first integrated healthcare company, bringing together imaging and lab diagnostics, therapy, and healthcare information technology solutions, supplemented by consulting and support services. Siemens Healthcare delivers solutions across the entire continuum of care – from prevention and early detection, to diagnosis, therapy and care. Additionally, Siemens Healthcare is the global market leader in innovative hearing instruments. The company employs around 49,000 people worldwide and operates in 130 countries. In the fiscal year 2008 (Sept. 30), Siemens Healthcare reported sales of €11.2 billion, orders of €11.8 billion, and Sector profit of €1.2 billion. Further information can be found by visiting www.siemens.com/healthcare
*This product does not yet fulfill all the essential requirements according to the European Medical Device Directive (93/42/EEC) and its national implementations. It is not yet commercially available in the European Union.